Outlook Therapeutics (NASDAQ:OTLK) Announces Earnings Results

Outlook Therapeutics (NASDAQ:OTLK) released its earnings results on Friday. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.04), Zacks reports.

Outlook Therapeutics Stock Performance

OTLK opened at $1.87 on Friday. Outlook Therapeutics has a 12 month low of $0.87 and a 12 month high of $12.85. The stock’s 50 day moving average price is $1.88 and its 200 day moving average price is $4.47.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on OTLK shares. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Outlook Therapeutics in a report on Friday, January 17th. BTIG Research cut their price target on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 29th. Chardan Capital reissued a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. Finally, Guggenheim reissued a “buy” rating and issued a $12.00 price target on shares of Outlook Therapeutics in a report on Friday, January 17th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.40.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.